Avaliação do Potencial Cardiotóxico do Vp-16 Através de um Modelo Experimental Utilizando Ratas Albinas: Discussão de Achados Anátomo-Patológicos

• Autor(a) principal: Schvvartsmann, Gilberto
• Data de Publicação: 2023
• Outros Autores: Silva, Carmem Lúcia Oliveira da, Teixeira, Lucas P., Rangel, Luiza, Gurski, Richard R., Segal, Fábio, Coutinho, Ligia B., Marques, Maria
• Tipo de documento: Artigo
• Idioma: por
• Título da fonte: Revista Brasileira de Cancerologia (Online)
• Texto Completo: https://rbc.inca.gov.br/index.php/revista/article/view/3323
• topic: VP-16; Cardiotoxicidade; Vp-16; Cardiotoxicity

Based on anedoctal reports from the literature suggesting cardiotoxicity due to VP-16, the authors studied the effects on an eight-weekiy intraperitoneal (IP) injection of VP-16 in a group of fifty Albine rats, compared to Controls receiving isotonic saline during the same period of time. Group A (VP-16) received 5mg/kg weight IP weekly for eight courses. Group B (isotonic saline) had the same volume in isotônic saUne IP. Animais from Group A were killed at two-weekly intervals, according to sub-groups G1, G2, G3, G4 and G5 (10 rats in each interval). Animals from Group B were sacrified at the end of experiment. Anatomopathological studies of myocardium from Group A failed to show significant differences between subgroups, in spite of increasing total dosis. When both groups were compared, there were no statystical differences between the animals from Group A and B (P less 0.05). The authors conclude that there is no significant cardiac damage during the VP-16 therapy, at least in experimental conditions. The case reports found in the literature suggesting the possibility of cardiac damage due to VP-16 are probably secondary to unrelated factors.